TEMPORARY REMOVAL: PO-32: Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models
Blower, E L, Castle, J, Santiago-Gomez, A, Clarke, R B, Kirwan, C C
Published in Thrombosis research (01.05.2022)
Get full text
Published in Thrombosis research (01.05.2022)
Journal Article
TEMPORARY REMOVAL: OC-09: Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial
Kirwan, C C, Castle, J, Pritchard, S A, Bundred, N J, Thachill, J, Harvey, J R, Roy, P G, Volleamere, A, Blower, E L, Palmieri, C, Hogan, B, Vinayagam, R, Cox, K, Marshall, A, Turner, L, Gibson, G, Scott, H, Holcombe, C
Published in Thrombosis research (01.05.2022)
Get full text
Published in Thrombosis research (01.05.2022)
Journal Article